Trials / Completed
CompletedNCT00643799
Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis
A Randomized, Multicenter, Double-Blind, Double-Dummy Study Comparing the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Naproxen 500 mg Twice Daily in the 6-month Treatment of Subjects With Osteoarthritis of the Knee
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 586 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | 200 mg oral capsule once daily for 6 months |
| DRUG | Naproxen | 500 mg oral capsule twice daily for 6 months |
| DRUG | Placebo | Matched oral placebo for 6 months |
Timeline
- Start date
- 2004-03-01
- Primary completion
- 2005-01-01
- Completion
- 2005-01-01
- First posted
- 2008-03-26
- Last updated
- 2021-02-02
Locations
51 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00643799. Inclusion in this directory is not an endorsement.